Astellas Pharma could secure the exclusive global rights to Audax Biosciences’ DAX-044, an antibody-cytokine fusion therapy that activates the immune system in the vicinity of the tumor.
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset